与质子抑制剂相关的不良风险:系统性审查
Joel J Heidelbaugh1, Kathleen L Goldberg2, John M Inadomi3
1Dr. Heidelbaugh serves as Clinical Associate Professor in the Department of Family Medicine at the University of Michigan in Ann Arbor, Michigan.
Gastroenterology & hepatology
|November 15, 2023
概括
质子抑制剂 (PPI) 广泛用于上部胃肠道问题. 这次审查强调了PPI治疗的潜在风险,包括感染,骨折和营养缺乏,建议谨慎使用.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 质子抑制剂 (PPI) 经常用于上部胃肠道疾病.
- 它们占处方药和非处方药销售的很大一部分.
研究的目的:
- 系统地审查文献,进行严格的研究,将PPI治疗与不良事件联系起来.
- 评估与短期和长期PPI使用相关的潜在风险.
主要方法:
- 使用MEDLINE数据库进行了系统的文献审查.
- 审查的重点是确定检查PPI相关不良事件的高质量研究.
主要成果:
- 新出现的证据将PPI治疗与增加*Clostridium difficile*相关的腹风险联系在一起.
- 潜在的风险包括社区获得的肺炎,骨质疏松性骨折和维生素B12缺乏.
- PPI也可能抑制抗血小板治疗的有效性.
结论:
- 临床医生应该定期重新评估患者对PPI治疗的持续需求.
- 建议使用最低有效的PPI剂量,以尽量减少潜在的不良事件.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
438
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
438
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
438
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
438
Peptic Ulcer Disease IV: Management
96
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
96
Peptic Ulcer Disease I: Introduction
179
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
179
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
490
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
490
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
458
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
458


